Cytokinetics
CYTK
$71.93
+0.74%
Cytokinetics Inc. is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors for debilitating diseases where muscle performance is compromised, including heart failure, amyotrophic lateral sclerosis, and spinal muscular atrophy. As a pioneer in muscle biology, the company's lead product, MYQORZO (omecamtiv mecarbil), targets cardiac myosin and has established Cytokinetics as a key player in the cardiovascular space. The current investor narrative centers on the commercial launch of MYQORZO, which is driving revenue growth, alongside the advancement of its pipeline, particularly aficamten for hypertrophic cardiomyopathy, which has shown promising clinical data and is expected to be a major growth catalyst. The stock has been volatile, reflecting both the potential of its pipeline and the challenges of commercial execution in a competitive market.…
CYTK
Cytokinetics
$71.93
Related headlines
CYTK 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cytokinetics's 12-month outlook, with a consensus price target around $109.90 and implied upside of +52.8% versus the current price.
Average Target
$109.90
0 analysts
Implied Upside
+52.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$85 - $146
Analyst target range
Cytokinetics is covered by 20 analysts, with a consensus recommendation of 'Strong Buy' (mean rating 1.5). The average target price is $109.90, implying a substantial upside of +52.4% from the current price of $72.09. The distribution is heavily bullish, with no sell ratings, and recent actions include upgrades from UBS (Neutral to Buy) and reaffirmations of Outperform/Buy ratings from RBC, Mizuho, and others, indicating strong positive sentiment. The target price range spans from $85.00 (low) to $146.00 (high), with the high target suggesting the potential for a doubling of the stock price, likely based on successful aficamten approval and peak sales estimates. The wide spread of $61 between low and high targets reflects significant uncertainty regarding the commercial trajectory of MYQORZO and the regulatory path for aficamten, but the overall bullish consensus underscores confidence in the company's pipeline and market opportunity.
Bulls vs Bears: CYTK Investment Factors
Cytokinetics presents a high-risk, high-reward profile typical of late-stage biotech. The bull case is anchored by a Strong Buy consensus, a 52% upside to average targets, and the commercial launch of MYQORZO with a high gross margin. However, the bear case is equally compelling: a PS ratio of 86.6x versus the industry's 5.0x, deep losses, and negative equity create substantial downside risk. Currently, the bull side has stronger evidence given the analyst conviction and pipeline catalysts, but the single most important tension is whether MYQORZO sales can ramp fast enough to justify the valuation. If revenue growth disappoints, the stock could see a sharp correction toward the 52-week low of $35.22.
Bullish
- Strong Buy consensus with 52% upside: 20 analysts rate CYTK a Strong Buy (mean 1.5) with an average target of $109.90, implying +52.4% upside from $72.09. No sell ratings and recent upgrades from UBS and others underscore positive sentiment.
- MYQORZO launch driving revenue growth: Q1 2026 revenue grew 11.3% YoY to $19.4M, driven by initial MYQORZO sales. This marks a transition from near-zero revenue to commercial stage, with gross margin at 87.6% indicating scalable product economics.
- Aficamten pipeline catalyst ahead: Aficamten for hypertrophic cardiomyopathy has shown promising clinical data and is expected to be a major growth driver. Analyst high target of $146 implies potential doubling, reflecting peak sales estimates for this asset.
- Strong liquidity with current ratio 4.53: Current ratio of 4.53 indicates ample short-term liquidity to fund operations, reducing near-term bankruptcy risk despite negative cash flow. This provides a runway for pipeline milestones.
Bearish
- Extreme valuation at 86.6x sales: PS ratio of 86.6x is 17x the industry average of 5.0x, implying the market expects explosive revenue growth. Any miss on commercial execution could trigger severe multiple compression.
- Deep losses and negative cash flow: Q1 2026 net loss of $206M and TTM FCF of -$548.9M indicate heavy cash burn. Operating margin at -695% shows expenses far outpace revenue, requiring continuous external financing.
- High debt with negative equity: Debt-to-equity ratio of -1.95 reflects negative shareholders' equity due to accumulated losses. This financial structure increases vulnerability to interest rate hikes and refinancing risks.
- Recent price pullback and volatility: Stock fell 7.5% on Aug 28, 2026, and is down 8% over the past month, underperforming the S&P 500 by 13.5%. This suggests profit-taking and potential short-term overextension after the rally.
CYTK Technical Analysis
Cytokinetics has exhibited a strong uptrend over the past year, with the stock price surging 93.0% from 52-week lows, currently trading at $72.09, which is 81.6% of its 52-week range (low $35.22, high $88.31). This positioning near the upper end of the range indicates robust momentum and investor optimism, though it also suggests the stock may be overextended in the short term. The 6-month price change of +15.9% confirms the longer-term bullish trend, but the stock has pulled back from its June peak of $87.26, indicating a potential consolidation phase.
Beta
0.38
0.38x market volatility
Max Drawdown
-18.7%
Largest decline past year
52-Week Range
$47-$88
Price range past year
Annual Return
+45.0%
Cumulative gain past year
| Period | CYTK Return | S&P 500 |
|---|---|---|
| 1m | -5.9% | +1.0% |
| 3m | -0.5% | +1.1% |
| 6m | +19.1% | +13.8% |
| 1y | +45.0% | +19.5% |
| ytd | +16.5% | +12.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CYTK Fundamental Analysis
Cytokinetics' revenue trajectory is improving, with Q1 2026 revenue of $19.4 million, up 11.3% year-over-year, driven by initial sales of MYQORZO and collaboration revenues. However, the company remains deeply unprofitable, with a net loss of $206.0 million in Q1 2026, translating to an EPS of -$1.67. Gross margin is high at 87.6%, reflecting the low cost of goods for biopharmaceuticals, but operating margin is deeply negative at -695.4% due to heavy R&D and SG&A expenses. The company's balance sheet shows a current ratio of 4.53, indicating strong short-term liquidity, but a negative debt-to-equity ratio of -1.95 suggests a high level of debt relative to shareholders' equity, which is negative due to accumulated losses. Free cash flow is deeply negative at -$548.9 million TTM, indicating the company is heavily reliant on external financing to fund operations, a common characteristic of late-stage biotech companies.
Quarterly Revenue
$19355000.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
87.6%
Latest Quarter
Free Cash Flow
$-548921999.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CYTK Overvalued?
Given the company's negative net income, the price-to-sales (PS) ratio is the most appropriate valuation metric, currently at 86.6x trailing, which is extremely high and reflects the market's expectation of significant future revenue growth. The forward PE is -16.2x, but this is not meaningful due to expected losses. Compared to the industry average PS ratio of 5.0x (from valuation data), Cytokinetics trades at a massive premium, indicating that the market is pricing in a highly successful commercial launch and pipeline success. Historically, the PS ratio has ranged from 37.9x to 13,420x over the past few years, with the current level near the lower end of that range, suggesting that while the stock is expensive on an absolute basis, it is relatively cheaper than its own historical extremes, which were driven by minimal revenue. This valuation implies that investors are betting on a rapid revenue ramp, and any disappointment in commercial execution could lead to significant multiple compression.
PE
-9.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-11.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are severe: CYTK reported a net loss of $206M in Q1 2026 and TTM free cash flow of -$548.9M, indicating heavy reliance on external financing. The negative debt-to-equity ratio of -1.95 reflects negative shareholders' equity, and the operating margin of -695% shows expenses vastly exceed revenue. While the current ratio of 4.53 provides short-term liquidity, the company's cash burn rate of over $500M annually could require dilutive capital raises within 12-18 months, pressuring the stock price.